Disclosed is the use of estradiol valerate or 17-beta-estradiol in combination with 17-alpha-cyanomethyl-17-beta-hydroxyestra-4,9-dien-3-one (dienogest), for producing a multiphase combination product or a single-phase combination product for oral therapy for treating decreased female libido.